BioSpace News Archive

Viseon Inc. announces the completion of an insider financing round. The financing will enable further 4K-ADV™ product development and market expansion focusing on several exciting fronts where digitization of open and minimally invasive surgery can facilitate clinical and economic benefits.

Pharvaris recently presented data highlighting the unique pharmacological and clinical properties of deucrictibant for the treatment and prevention of HAE attacks at the 20th Annual Congress of International Drug Discovery Science and Technology ; the 2024 Eastern Allergy Conference ; and the European Academy of Allergy and Clinical Immunology Congress 2024.

CytoSorbents Corporation announces the recent data presentation entitled “Early CABG with Intraoperative Haemoadsorption in Patients on Ticagrelor: The Safe and Timely Antithrombotic Removal Registry,” at the international EuroPCR 2024 conference in Paris, France - the world-leading course in interventional cardiovascular medicine with over 12,000 attendees - where it was also selected as a top 5 finalist in the best scientific abstract competition.

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, June 11, 2024.

Soleno Therapeutics, Inc. announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

Apollomics Inc., a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced a poster presentation and an oral presentation by partner company, Avistone Biotechnology, at the 2024 American Society of Clinical Oncology Annual Meeting, being held May 31-June 4, 2024, in Chicago, Ill. and virtually.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company’s cyclin-dependent kinase (CDK) 2/9 inhibitor, as a novel treatment for metastatic colorectal cancer (CRC).

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces that it has successfully adapted and extended the use of its bioreactor capabilities for production of another clinically and commercially-important test-ingredient.

23andMe Holding Co., a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance, the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration to help advance research on colorectal cancer in the Black/African American community.

Genetic Signatures Limited announces that the US Food & Drug Administration (“FDA”) has cleared the Company’s EasyScreen ™ Gastrointestinal Parasite Detection Kit and GS1 automated workflow [1] for marketing and sale in the US.